ArticleColombia medica (Cali, Colombia)2015
Analysis of the LRRK2 p.G2019S mutation in Colombian Parkinson's Disease Patients.
Article in Colombia medica (Cali, Colombia), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Genetic risk variants in New Yorkers of Puerto Rican and Dominican Republic heritage with Parkinson's disease.NPJ Parkinson's disease · 2023Article
- Mitophagy in Human Diseases.International journal of molecular sciences · 2021Review
- Genetic characterization of Parkinson's disease patients in Ecuador and Colombia.Parkinsonism & related disorders · 2020Article
- Novel Variants inFrontiers in neurology · 2020Article
- Mechanisms and roles of mitophagy in neurodegenerative diseases.CNS neuroscience & therapeutics · 2019Review
- Motivations for Participation in Parkinson Disease Genetic Research Among Hispanics versus Non-Hispanics.Frontiers in genetics · 2019Article
- A Comprehensive Analysis of Population Differences inFrontiers in aging neuroscience · 2019Article
- Variable frequency ofNPJ Parkinson's disease · 2017Article
- Resequencing analysis of five Mendelian genes and the top genes from genome-wide association studies in Parkinson's Disease.Molecular neurodegeneration · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionMutations in the leucine-rich repeat kinase 2 gene (LRRK2 or Dardarin) are considered to be a common cause of autosomal dominant and sporadic Parkinson´s disease, but the prevalence of these mutations varies among populations.
objectiveto analyzed the frequency of the LRRK2 p.G2019S mutation (c.6055 G>A transition) in a sample of Colombian patients.
methodsIn the present study we have analyzed the frequency of the LRRK2 p.G2019S mutation in 154 patients with familial or sporadic Parkinson Disease, including early and late onset patients, and 162 normal controls.
resultsOur results show occurrence of this mutation in two cases (2/154, 1.3%) with classical Parkinson´s signs, and one completely asymptomatic control (1/162, 0.6%).
conclusionThe p.G2019S mutation is not an important causal factor of Parkinson Disease in Colombia having similar frequencies to those reported in other Latin American populations.
Indexed as
Identifiers
26600626PMC4640433What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.